GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Emergent BioSolutions
Emergent BioSolutions is a biopharmaceutical company specializing in public health products such as vaccines and antidotes. Its stock price reflects government biodefense contracts, but also serious production issues that have tarnished its reputation.
Share prices of companies in the market segment - Pharma virus
Emergent BioSolutions is a company specializing in the development and production of vaccines and therapeutics to protect against bioterrorism threats and infectious diseases. We classify it as a "Viral Pharmaceuticals" company. The chart below shows the overall dynamics of this strategically important sector.
Broad Market Index - GURU.Markets
Emergent BioSolutions develops and produces vaccines and therapeutics to protect against public health threats such as anthrax and smallpox. As a key government partner, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with Emergent's performance.
Change in the price of a company, segment, and market as a whole per day
EBS - Daily change in the company's share price Emergent BioSolutions
Daily fluctuations in Emergent BioSolutions, a biopharmaceutical company, reflect its dependence on government contracts, particularly for vaccines. Change_co shows high sensitivity to government procurement news. This metric is the basis for biodefense sector analysis on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma virus
Emergent BioSolutions Inc. is a biotechnology company. This chart highlights the sector's high volatility. Comparing it to EBS, which focuses on public health and biodefense products, helps understand its reliance on government contracts.
Daily change in the price of a broad market stock, index - GURU.Markets
Emergent is a biopharmaceutical company specializing in products to protect against biological threats. Its business relies on government contracts. The chart below shows the overall market volatility, which may make Emergent appear more stable.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Emergent BioSolutions
Emergent BioSolutions' year-over-year performance is a story of reputational and operational challenges. The biopharmaceutical company's 12-month market cap reflects its struggle to restore trust after its vaccine production problems, as well as its reliance on government contracts for biodefense products, such as the anthrax vaccine.
Annual dynamics of market capitalization of the market segment - Pharma virus
Emergent BioSolutions Inc. is a company specializing in products to protect against public health threats, including vaccines and antidotes. Its business is based on government contracts. The chart below shows how its unique "defense" niche and dependence on government contracts influence its volatile performance.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Emergent, specializing in biodefense, has a unique business. Its stock price is unaffected by the economy, but soars on news of disease outbreaks and government procurement. The chart is a bet on a "black swan" event, one that could lie dormant for years and then deliver huge profits.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Emergent BioSolutions
Emergent, a biopharmaceutical company, depends on government contracts for its performance. The monthly fluctuations on the chart reflect the US government's demand for its vaccines and bioterrorism defense products, as well as its ability to recover from production problems.
Monthly dynamics of market capitalization of the market segment - Pharma virus
Emergent BioSolutions is a company specializing in the development of vaccines and therapeutics to protect against public health threats, including bioterrorism (such as anthrax). The graph below shows the dynamics of the biotech sector, where the company occupies an important niche through government contracts.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Emergent BioSolutions specializes in public health products, including vaccines and antidotes. Demand for its products is often driven by government contracts and biothreat preparedness. Share price movements may be unrelated to the market, but instead depend on news about pandemics or government procurement.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Emergent BioSolutions
Emergent BioSolutions is a biopharmaceutical company specializing in public health products, including vaccines and antidotes. Its weekly stock price is heavily influenced by government contracts and news related to biodefense and pandemics.
Weekly dynamics of market capitalization of the market segment - Pharma virus
Emergent BioSolutions, like the entire biodefense sector, responds weekly to industry-wide news about government contracts and pandemic threats. This chart shows how the company is positioned within the context of broader trends impacting the entire public health sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Emergent BioSolutions is a biopharmaceutical company that works, among other things, on government contracts in the biodefense sector. This should ensure stability. The chart shows how much the company's shares are protected from market volatility thanks to government contracts, which are essentially a defensive asset.
Market capitalization of the company, segment and market as a whole
EBS - Market capitalization of the company Emergent BioSolutions
The Emergent BioSolutions chart is a story of government contracts and production problems. Its market cap, once high thanks to its vaccine production, has plummeted due to quality issues. The chart clearly demonstrates how reputational risks can devastate a company's valuation.
EBS - Share of the company's market capitalization Emergent BioSolutions within the market segment - Pharma virus
Emergent BioSolutions occupies a unique market share, specializing in public health products such as anthrax vaccines and antidotes. Its profitability is heavily dependent on government contracts and biosecurity programs.
Market capitalization of the market segment - Pharma virus
Emergent BioSolutions specializes in biothreat defense. How big is this industry? The chart below shows the overall market capitalization of the viral pharmaceutical sector. Its dynamics often reflect government contracts and pandemic preparedness, making it strategically important yet volatile.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Emergent BioSolutions chart tells the story of a company that found itself in the spotlight during the pandemic. Its market capitalization reflects both revenue from vaccines and biohazard treatments, as well as reputational and production issues. This diagram shows how government mandates and crises are shaping the fate of a biopharmaceutical company.
Book value capitalization of the company, segment and market as a whole
EBS - Book value capitalization of the company Emergent BioSolutions
Emergent BioSolutions's material base consists of its production facilities for vaccines and biopharmaceuticals, including those for government contracts. The book value reflects the true value of these strategically important pharmaceutical assets. The chart below shows how the value of this production foundation has changed.
EBS - Share of the company's book capitalization Emergent BioSolutions within the market segment - Pharma virus
Emergent BioSolutions is a biopharmaceutical company whose assets include large-scale vaccine and biologics production facilities, including facilities for responding to public health threats. The chart shows the significant share of this strategically important manufacturing infrastructure in the US that the company controls.
Market segment balance sheet capitalization - Pharma virus
Emergent BioSolutions is a contract vaccine manufacturer (CDMO). The pharmaceutical industry, as the chart shows, is extremely capital-intensive. Emergent's business is the ownership and operation of large, certified biopharmaceutical manufacturing facilities.
Book value of all companies included in the broad market index - GURU.Markets
Emergent BioSolutions is a network of factories and laboratories for the production of vaccines and biopharmaceuticals, including for government needs. The chart below shows the evolution of this strategically important production base, prepared to respond to biothreats.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Emergent BioSolutions
Emergent BioSolutions' assets are vaccine production plants. Their valuation depends on government contracts and the company's ability to respond to biothreats. The chart shows how the market assessed these non-market, political factors.
Market to book capitalization ratio in a market segment - Pharma virus
Emergent BioSolutions is a company specializing in public health products, including vaccines and antidotes (such as opioid overdose treatments). The chart shows how the market values its product portfolio and government contracts.
Market to book capitalization ratio for the market as a whole
Emergent BioSolutions is a biopharmaceutical company specializing in public health products, including anthrax and smallpox vaccines. Its valuation, relative to the average, is driven by government contracts and its role in biosecurity. This is a unique niche where government relations trump market conditions.
Debts of the company, segment and market as a whole
EBS - Company debts Emergent BioSolutions
Emergent BioSolutions, a biopharmaceutical company specializing in public health products (vaccines, antidotes), has faced significant operational and financial challenges. This chart reflects its high debt load and efforts to restructure its business to restore confidence and financial stability.
Market segment debts - Pharma virus
Emergent BioSolutions is a biopharmaceutical company specializing in public health products, specifically vaccines and antidotes against biological and chemical threats. The business is heavily dependent on government contracts. This chart shows how its debt policy reflects this dependence and how it manages its capital following the challenges of COVID-19 vaccine production.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Emergent BioSolutions
Emergent BioSolutions is a biopharmaceutical company specializing in public health products, including vaccines. Its financial position can be heavily dependent on government contracts. This chart shows its debt level, which helps assess its financial stability and the risks associated with its reliance on large, but not always regular, orders.
Market segment debt to market segment book capitalization - Pharma virus
Emergent BioSolutions is a company specializing in public health products, including vaccines and antidotes. This chart shows the debt burden in the biotech sector. It helps understand how the company, which often works on government contracts, manages its finances and production capacity to combat biothreats.
Debt to book value of all companies in the market
Emergent BioSolutions operates in the biodefense field, developing vaccines and treatments against biological threats. Government contracts are a significant part of its business. This chart of total market debt provides context for assessing its financial stability. To what extent does its debt load depend on the stability of government contracts?
P/E of the company, segment and market as a whole
P/E - Emergent BioSolutions
Emergent BioSolutions is a company specializing in public health products, specifically anthrax and smallpox vaccines for the US Strategic National Stockpile. This chart reflects its reliance on government contracts. The dynamics also highlight reputational risks, as seen with COVID-19 vaccine production issues.
P/E of the market segment - Pharma virus
Emergent BioSolutions is a biomedical company specializing in public health products, specifically vaccines and antidotes against bioterrorism threats such as anthrax and smallpox. This chart shows the average valuation for the pharmaceutical sector, reflecting how investors value companies working on government biosecurity contracts.
P/E of the market as a whole
Emergent BioSolutions is a biopharmaceutical company specializing in public health products such as anthrax vaccines and antidotes. Its primary client is the US government. The company's valuation is largely independent of the general economic cycles reflected here, but is driven by government contracts and biosecurity priorities.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Emergent BioSolutions
Emergent BioSolutions is a company specializing in public health products, specifically vaccines and antidotes for bioterrorism threats (such as anthrax). This graph reflects expectations for government contracts. The company's valuation is heavily dependent on contracts with the US government and other countries.
%20P%2FE%20Emergent%20BioSolutions&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Emergent-BioSolutions&v=1772568230976 "Chart of the company's future (projected) P/E Emergent BioSolutions")
Future (projected) P/E of the market segment - Pharma virus
Emergent BioSolutions is a biopharmaceutical company specializing in public health products, specifically vaccines and antidotes for biological and chemical threats. This chart reflects the market's view of its complex and often controversial business. Comparing its profit forecasts to the sector reveals how investors value its government contracts.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-virus&v=1772568231054 "Future (projected) P/E graph of the market segment - Pharma virus")
Future (projected) P/E of the market as a whole
Emergent BioSolutions specializes in public health products, including vaccines and antidotes against bioterrorism threats. A significant portion of its revenue comes from government contracts. This general market sentiment curve has little impact on its core business, which is driven by government priorities in healthcare and defense.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772568231207 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Emergent BioSolutions
Emergent BioSolutions Inc. is a company specializing in public health products, specifically vaccines and antidotes against bioterrorism threats (such as anthrax). The company's revenue is heavily dependent on government contracts. This chart shows financial results related to government contracts and production issues.
Profit of companies in the market segment - Pharma virus
Emergent BioSolutions specializes in public health products, including vaccines and antidotes against biological and chemical threats. A significant portion of its business comes from government contracts. The profitability chart for the viral pharmaceuticals sector shows how governments' willingness to invest in biodefense and pandemic response impacts the entire industry.
Overall market profit
Emergent BioSolutions specializes in the development and production of products to protect against public health threats, including vaccines and antidotes against biological and chemical attacks. The company is a vital partner to the government in ensuring national security. Its activities reflect the country's level of preparedness for public health emergencies.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Emergent BioSolutions
Emergent BioSolutions is a company specializing in public health products, including vaccines and antidotes (such as Narcan for opioid overdose). This graph reflects expectations for government contracts and demand for its life-saving products.
%20profit%20of%20the%20company%20Emergent%20BioSolutions&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Emergent-BioSolutions&v=1772568231521 "Graph of future (projected) profit of the company Emergent BioSolutions")
Future (predicted) profit of companies in the market segment - Pharma virus
Emergent BioSolutions provides specialized products for civilian and military healthcare, including vaccines and antidotes against biothreats. The graph shows profit projections for the pharmaceutical sector. This allows us to assess the extent to which government demand for bioterrorism protection products supports business stability.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-virus&v=1772568231563 "Graph of future (predicted) profits of companies in a market segment - Pharma virus")
Future (predicted) profit of the market as a whole
The dynamics in this chart reflect expectations for a biopharmaceutical company specializing in public health products, including vaccines and antidotes. Emergent BioSolutions' profit outlook depends on government contracts, particularly for strategic stockpile replenishment. Reputational and production issues significantly impact results.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772568231588 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Emergent BioSolutions
Emergent BioSolutions is a biopharmaceutical company specializing in public health products, including anthrax and smallpox vaccines. This chart shows how investors value its government contract revenue. The multiple reflects both stability and dependence on government contracts.
P/S market segment - Pharma virus
Emergent BioSolutions specializes in public health products, including vaccines and antidotes against biological and chemical threats. Revenue often depends on government contracts. This chart shows the average valuation in the sector, helping to understand how the market views the company's unique niche and the stability of its revenue related to national security.
P/S of the market as a whole
Emergent BioSolutions is a company specializing in public health products, specifically vaccines and antidotes against bioterrorism threats. Its primary client is the US government. This chart, which displays the average revenue estimate for Emergent BioSolutions, helps understand how the market views its reliance on government contracts and the reputational risks it poses.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Emergent BioSolutions
Emergent BioSolutions is a company specializing in public health products, specifically vaccines and antidotes against biological and chemical threats. Its key client is the US government. This chart shows how investors estimate its future revenue, which is heavily dependent on government contracts and emergency preparedness programs.
%20P%2FS%20Emergent%20BioSolutions&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Emergent-BioSolutions&v=1772568231906 "The graph of the company's future (projected) P/S Emergent BioSolutions")
Future (projected) P/S of the market segment - Pharma virus
Emergent BioSolutions is a company specializing in public health products, including vaccines and antidotes against biological and chemical threats. This chart compares market expectations for its future revenue with those of other vaccine manufacturers. The valuation reflects investor opinions on its government contracts and production capabilities.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20virus&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-virus&v=1772568231997 "Future (projected) P/S market segment graph - Pharma virus")
Future (projected) P/S of the market as a whole
Emergent BioSolutions is a company specializing in public health products, including vaccines and antidotes for biological and chemical threats. Its revenue often depends on government contracts. The company's business is important for national security and pandemic preparedness, which are part of long-term government spending.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772568232101 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Emergent BioSolutions
Emergent BioSolutions is a biopharmaceutical company specializing in public health products, including vaccines and antidotes against bioterrorism threats. This chart reflects revenue from government contracts to supply its life-saving drugs to the national stockpile.
Sales of companies in the market segment - Pharma virus
Emergent BioSolutions is a company specializing in public health products, specifically vaccines and antidotes against bioterrorism threats such as anthrax. Its primary client is the US government. This chart shows overall pharmaceutical sales, reflecting government spending on biosecurity and pandemic preparedness.
Overall market sales
Emergent BioSolutions is a company specializing in public health products, specifically vaccines and antidotes against biological and chemical threats. Its key clients are governments. This overall economic activity impacts Emergent through government budgets allocated for biodefense and pandemic preparedness.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Emergent BioSolutions
Emergent BioSolutions is a biopharmaceutical company specializing in public health products, including anthrax and smallpox vaccines, as well as the opioid overdose reversal drug Narcan. This chart reflects analysts' expectations for government procurement and demand for these vital medications.
%20sales%20of%20the%20company%20Emergent%20BioSolutions&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Emergent-BioSolutions&v=1772568232342 "Schedule of future (projected) sales of the company Emergent BioSolutions")
Future (projected) sales of companies in the market segment - Pharma virus
Emergent BioSolutions is a company specializing in public health products, including vaccines and antidotes against bioterrorism threats. This chart shows projected revenue for the entire pharmaceutical sector. While it reflects general trends, Emergent's business is heavily dependent on government contracts and pandemic preparedness.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-virus&v=1772568232362 "Schedule of future (projected) sales of companies in the market segment - Pharma virus")
Future (projected) sales of the market as a whole
Emergent BioSolutions is a company specializing in public health products, particularly vaccines and antidotes against bioterrorism threats. Its primary client is the US government. This graph, reflecting the state of the economy, influences the government budget. However, national security spending is often a priority and less dependent on economic cycles.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772568232371 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Emergent BioSolutions
Emergent BioSolutions specializes in public health products, including anthrax and smallpox vaccines. The chart reflects profitability, which is largely dependent on government contracts. The company's performance is determined by the stability of government contracts and the ability to efficiently produce critical biologics.
Market segment marginality - Pharma virus
Emergent BioSolutions specializes in public health products, particularly vaccines and antidotes against biological and chemical threats. The company frequently works with government contracts. This chart shows its operational efficiency, reflecting its ability to produce critical drugs and manage long-term government contracts.
Market marginality as a whole
Emergent BioSolutions is a biomedical company specializing in public health products, including vaccines and antidotes against bioterrorism threats. The company's profitability often depends on government contracts. This total market return chart highlights Emergent's unique business model, which is focused on national security needs rather than the traditional commercial market.
Employees in the company, segment and market as a whole
Number of employees in the company Emergent BioSolutions
Emergent BioSolutions is a company specializing in public health products, specifically vaccines and antidotes for biological and chemical threats. This graph shows a team working on major government contracts. The staffing dynamics may be related to fulfilling orders for the Strategic National Stockpile.
Share of the company's employees Emergent BioSolutions within the market segment - Pharma virus
This figure reflects Emergent BioSolutions' focus on public health. The company's workforce in this sector is focused on developing and manufacturing products to protect against bioterrorism threats (such as anthrax vaccines) and opioid overdose (Narcan). This team works closely with the US government to address critical public health challenges.
Number of employees in the market segment - Pharma virus
Emergent BioSolutions is a company specializing in public health products, particularly vaccines and antidotes against bioterrorism threats. The company frequently works on government contracts. This chart shows how national security objectives create jobs in the biotech sector for scientists and manufacturing personnel.
Number of employees in the market as a whole
Emergent BioSolutions Inc. specializes in public health products, including vaccines and antidotes. Demand for its products is driven by government procurement and biothreat preparedness, not by the labor market, as shown in this chart. The company is a national security asset.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Emergent BioSolutions (EBS)
Emergent BioSolutions specializes in public health products, including vaccines and antidotes. This chart reflects its complex business. Its moderate capitalization per employee may be due to the presence of both R&D units and large manufacturing facilities necessary for fulfilling government contracts.
%20of%20the%20company%20Emergent%20BioSolutions%20(EBS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Emergent-BioSolutions-EBS&v=1772568232759 "Chart of market capitalization per employee (in thousands of dollars) of the company Emergent BioSolutions (EBS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma virus
Emergent BioSolutions specializes in public health products, including vaccines and antidotes. This cost per employee metric reflects the value of its manufacturing contracts and product portfolio. This sector comparison helps understand the company's unique position as a partner to governments in biodefense matters.
%20by%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-virus&v=1772568232810 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma virus")
Market capitalization per employee (in thousands of dollars) for the overall market
Emergent BioSolutions is a company specializing in public health products, specifically vaccines and antidotes against bioterrorism threats. This chart reflects its reliance on government contracts. The high employee valuation may be due to long-term and lucrative government contracts.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772568232859 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Emergent BioSolutions (EBS)
Emergent BioSolutions (EBS) is a company at the center of the COVID vaccine scandals. Their core business is "biodefense" products (anthrax vaccine, Narcan antidote). This chart shows profitability in the B2G segment (government contracts). It is highly volatile and dependent on government contracts.
%20Chart%20Emergent%20BioSolutions%20(EBS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Emergent-BioSolutions-EBS&v=1772568232884 "Company Profit Per Employee (in thousands of dollars) Chart Emergent BioSolutions (EBS)")
Profit per employee (in thousands of dollars) in the market segment - Pharma virus
Emergent BioSolutions (EBS) is a company specializing in public health products, specifically vaccines and antidotes against biothreats (e.g., anthrax, smallpox). This chart shows how effectively the company monetizes its contracts, often with government agencies. It serves as a benchmark for assessing the profitability of this niche business model compared to traditional pharmaceuticals.
%20in%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-virus&v=1772568232918 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma virus")
Profit per employee (in thousands of dollars) for the market as a whole
Emergent BioSolutions (EBS) is a company specializing in public health products, specifically anthrax vaccines and antidotes (Narcan). This chart reflects their reliance on government contracts. When the government purchases their products for the national stockpile, their profit per employee is high. However, production issues (as with the COVID vaccine) can devastate this metric.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772568232950 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Emergent BioSolutions (EBS)
Emergent BioSolutions is a biopharmaceutical company specializing in public health products, including anthrax and smallpox vaccines. This chart shows the company's performance under government contracts. Revenue per employee is heavily dependent on government contracts to replenish strategic stockpiles.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Emergent-BioSolutions-EBS&v=1772568233031 "Sales chart per company employee Emergent BioSolutions (EBS)")
Sales per employee in the market segment - Pharma virus
Emergent BioSolutions is a company specializing in public health products, specifically vaccines and antidotes (such as Narcan for overdose). This chart shows the average revenue per employee in this segment. It demonstrates the productivity of their manufacturing and R&D divisions in this niche area.
Sales per employee for the market as a whole
Emergent BioSolutions is a CDMO (contract manufacturer) for biopharma and also the owner of its own products (such as an anthrax vaccine). They rose to prominence (and infamy) during the pandemic. This chart shows the revenue generated by their factories producing complex vaccines and drugs for other companies and the government.
Short shares by company, segment and market as a whole
Shares shorted by company Emergent BioSolutions (EBS)
Emergent BioSolutions (EBS) is a company specializing in vaccines and antidotes (including Narcan, an overdose treatment). The bearish sentiment seen in this chart is due to reputational losses (the failure of J&J's vaccine production) and dependence on government contracts, which may not be renewed.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Emergent-BioSolutions-EBS&v=1772568233241 "Short Shares Chart for the Company Emergent BioSolutions (EBS)")
Shares shorted by market segment - Pharma virus
Emergent BioSolutions is a company specializing in biodefense (anthrax and smallpox vaccines, and antidotes). It is known for its COVID vaccine production issues. This chart shows the overall sentiment in the sector. It reflects investor concerns about the company's reputational risks and the instability of government biodefense contracts.
Shares shorted by the overall market
Emergent BioSolutions (EBS) specializes in public health products, including anthrax vaccines and the antidote Narcan. The business is heavily dependent on government contracts. Despite this "protective" component, EBS shares are susceptible to general market panic. This chart shows when fear becomes pervasive, dragging down even non-cyclical sectors.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Emergent BioSolutions (EBS)
Emergent BioSolutions is a company known for its biodefense contracts with the US government (anthrax vaccines, the opioid overdose drug Narcan). This chart measures how investors evaluate these "government contracts." It shows when the stock is "overbought" on contract news or "oversold" on manufacturing scandals.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Emergent-BioSolutions-EBS&v=1772568233529 "RSI 14 indicator chart for the company's stock Emergent BioSolutions (EBS)")
RSI 14 Market Segment - Pharma virus
Emergent BioSolutions (EBS) specializes in public health products, including a smallpox vaccine and Narcan (an opioid overdose treatment). They are also a major contract manufacturer (CDMO) for the government. This chart shows the overall sentiment in the biodefense and pharmaceutical sectors. It helps assess whether the entire segment is overheated.
RSI 14 for the overall market
Emergent BioSolutions (EBS), a vaccine manufacturer (for example, against anthrax), prioritizes this schedule less than government contracts. Its business is "biodefense." During times of panic (biohazards, pandemics), demand for its products soars. In the euphoria, investors and governments may forget about "defense," which reduces its revenue.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast EBS (Emergent BioSolutions)
Emergent BioSolutions (EBS) is a company specializing in public health solutions. It produces vaccines and antidotes against threats such as anthrax and smallpox (for governments), as well as Narcan (for overdose). This chart shows the average Wall Street forecast. It reflects analyst estimates for government procurement and Narcan sales.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-EBS-Emergent-BioSolutions&v=1772568233618 "A chart showing analyst consensus forecasts for the expected stock price. EBS (Emergent BioSolutions)")
The difference between the consensus estimate and the actual stock price EBS (Emergent BioSolutions)
Emergent BioSolutions (EBS) is a biopharmaceutical company known for its opioid overdose treatment Narcan and its biohazard contracts with the US government. This chart shows their reversal rate. It measures the gap between the price and the consensus target, reflecting whether analysts believe they can recover.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-EBS-Emergent-BioSolutions&v=1772568233653 "A chart showing the difference between the consensus forecast and the actual stock price. EBS (Emergent BioSolutions)")
Analyst consensus forecast for stock prices by market segment - Pharma virus
Emergent BioSolutions is a company best known for producing Narcan (an opioid overdose reversal spray) and anthrax vaccines for the US government. This chart shows analysts' overall expectations for the entire pharmaceutical sector (vaccines). It reflects whether experts believe there will be stable demand for national security products.
Analysts' consensus forecast for the overall market share price
Emergent BioSolutions (EBS) is a biopharmaceutical company specializing in public health products, specifically anthrax vaccines and Narcan (an overdose treatment). This chart shows overall market sentiment. For EBS, whose business relies heavily on government contracts (strategic reserve), overall optimism is important, but government decisions carry more weight.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Emergent BioSolutions
Emergent BioSolutions (EBS) is a company that failed during COVID (problems with J&J vaccine production). Their legacy is US government biodefense contracts (anthrax vaccines, Narcan antidote). This chart is a story of survival. It reflects their attempts to restore their reputation and their reliance on renewed government contracts.
AKIMA Market Segment Index - Pharma virus
Emergent (EBS) is a strategic B2G biotech company; the company is a key supplier to the US government in biodefense, producing anthrax and smallpox vaccines (as well as Narcan overdose protection). This summary metric measures R&D. The graph shows the segment average. This benchmark: how does this unique (B2G, biodefense) model (EBS) differentiate it from the average pharma company?
The AKIM Index for the overall market
Emergent BioSolutions is a biopharmaceutical company specializing in public health threats (anthrax, opioids - Narcan). This chart, reflecting the market average, provides a macro backdrop. It helps assess how EBS, which is dependent on government contracts and the antidote market, compares to the overall macroeconomic situation.
